Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
Amount Raised
$78 Million
Round Type
Series A
San DiegoBiotechnologyHealth CareTherapeuticsDescription
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies, announced today the launch of the company with the close of a $78 million Series A financing. The financing was co-led by 5AM Ventures, venBio Partners, and RA Capital Management, and joined by Medivate Partners and seed investors and strategic partners GC LabCell (Green Cross LabCell Corporation) (KRX: 144510) and GC (Green Cross Holdings Corporation) (KRX: 005250). Artiva will use the proceeds of this financing to develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies.
Quick answer
Artiva Biotherapeutics raised $78 Million in a Series A round, dated June 26, 2020. Artiva Biotherapeutics is based in San Diego, California, United States.
- How much did Artiva Biotherapeutics raise?
- Artiva Biotherapeutics raised $78 Million in a Series A round on June 26, 2020.
- What does Artiva Biotherapeutics do?
- Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.
- Where is Artiva Biotherapeutics based and how big is it?
- Artiva Biotherapeutics is based in San Diego, California, United States. Fundz records about 95 employees.
- Who are the decision-makers at Artiva Biotherapeutics?
- Fundz holds 1 contact at Artiva Biotherapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Artiva Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Biohaven raised $450M (Funding Round) on August 7, 2020.
- ADARx Pharmaceuticals, Inc. raised $5M on August 7, 2020.
- Kinnate Biopharma raised $88M on August 4, 2020.
- Oncotelic Therapeutics raised $2M (Seed) on August 4, 2020.
- GENOCEA BIOSCIENCES, INC. raised $76M on August 3, 2020.
- MBX Biosciences, Inc. raised $26M on July 27, 2020.
Who to call at Artiva Biotherapeutics, and when
A new round usually means Artiva Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Artiva Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Artiva Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Artiva Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Artiva Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansArtiva Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.